Pioglitazone Tablets USP — Class II drug recall D-0450-2022
Terminated recall by Aurobindo Pharma USA Inc., reported 2022-02-02, distributed nationwide. Superpotent and Failed Tablet/Capsule Specifications
| Recall number | D-0450-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Aurobindo Pharma USA Inc., East Windsor, NJ, United States |
| Recall initiated | 2021-12-29 |
| Classified | 2022-01-24 |
| Reported by FDA | 2022-02-02 |
| Terminated | 2023-12-04 |
| Distributed | Nationwide (US) |
| Quantity | 792 bottles |
| Reason classes | potency |
| NDC | 57237-0219, 57237-0219-05, 57237-0219-30, 57237-0219-90, 57237-0220, 57237-0220-05, 57237-0220-30, 57237-0220-90, 57237-0221, 57237-0221-05, 57237-0221-30, 57237-0221-90 |
| Lot numbers | PF4520028A, PF4520028B |
| Expiration dates | 2022-11 |
Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Reason for recall
Superpotent and Failed Tablet/Capsule Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0450-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.